You are here

Intravenous-to-Subcutaneous Drug Repositioning

NEW YORK, March 19, 2019 /PRNewswire/ -- As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection.

Read the full report: https://www.reportlinker.com/p05757676/?utm_source=PRN

While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration path is now becoming a significant pathway in the life cycle of many parenteral drugs. A number of technology approaches are currently being employed to accomplish this migration. By pursuing IV-to-SC strategies, drug owners are finding they can achieve a number of competitive advantages.

What You Will Learn
• What intravenous drugs have been strategically re-engineered for subcutaneous administration, what are the technologies being used, and what is their current market status?
• What are the therapeutic markets that are viewed as having the greatest potential for IV-to-SC migration?
• What are the major factors driving intravenous-to-subcutaneous drug re-engineering?
• How are intravenous-to-subcutaneous drugs currently aligned with drug classes and therapeutic markets?
• What intravenous drugs are currently being developed for eventual release as subcutaneously administered drugs, and what is their current status?
• What is the market impact of IV-to-SC drug migration? What will it be in 2024?
• Who are the significant players in this segment? What are their strategies? Who are their alliance partners?

Read the full report: https://www.reportlinker.com/p05757676/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/intravenous-to-subcutaneous-drug-repositioning-300814944.html

SOURCE Reportlinker